Αρχική World News Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced... World News Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression Από Ogkologos - 16 Ιουλίου, 2025 801 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR The Doctor Will See You Now…On the Screen 2 Ιουλίου, 2020 Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... 26 Ιουνίου, 2019 Pembrolizumab Combinations Show Promise in mCRPC 21 Νοεμβρίου, 2020 Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities 22 Οκτωβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Kid Friendly Meals Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients...
